Physician profile
Daniela Pisacane
NPI 1538455902
$6,098.79
in general payments reported to CMS, 2019-2025
42 companies · $769 in 2025
The $769 reported for 2025 was more than what 80% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,454 · 2022: $1,426 · 2023: $1,370 · 2024: $1,080 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,829.11 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $648.54 | 2022-2025 | Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $430.09 | 2021-2023 | Seglentis, Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.87 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $371.94 | 2021-2024 | |
| Glaxosmithkline, LLC. | $297.42 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Exact Sciences Corporation | $246.25 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $245.55 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $201.63 | 2021 | |
| Amgen INC. | $149.22 | 2022-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $140.62 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $133.60 | 2021-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $96.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $87.85 | 2021-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $87.64 | 2021-2025 | Capvaxive, Steglatro, Belsomra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Pisacane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.